CELCUITY INC (CELC)
Health Care · biotechnology · NASDAQ
Celcuity is a biotechnology company developing gedatolisib, a targeted PI3K/mTOR inhibitor, to treat various cancer indications.
What CELCUITY INC does
Celcuity is a clinical-stage biotechnology company focused on the development and commercialization of targeted therapies for cancer patients. Its lead product candidate is gedatolisib (brand name REVTORPYK), a potent inhibitor of PI3K/mTOR, which the company is evaluating in various clinical trials for cancer treatment. The company holds exclusive global rights for the development and commercialization of gedatolisib through a license agreement with Pfizer.
Themes: oncology, targeted cancer therapy, PI3K/mTOR pathway inhibitors, clinical-stage biopharma
Fundamentals
- Price$67.87 as of 2026-10-08 close
- Market cap$3.3B as of 2026-08-05 (share count; price 2026-10-08)
- 1-year return+37.1% 2025-10-08 close $49.50 → 2026-10-08 close $67.87
- P/En/a negative earnings
- ROE-176.1% FY2025, SEC XBRL
- Debt / equity6.04 as of 2026-09-03
- Beta1.11 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CELC compares in its sector
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CELCUITY INC looks technically
CELCUITY INC (CELC) is trading 34.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 48 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 55.1% below its highest point of the past year. Trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 34.7% below its 200-day average, the long-term trend line — a long-term downtrend | -34.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $86.22 | $86.22 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $103.95 | $103.95 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 35 calendar days ago — the swings before that are what the structure reading is measured on | 35 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 98. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 48 trading days ago — a "death cross", a bearish long-term signal | 48 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 23.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30) | 30.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($63.23 to $88.68) — its "stochastic" reading is 18 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 18.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 21 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $151.02 | $151.02 |
|---|---|---|
| From the 52-week high | it is 55.1% below its 52-week high (its highest price of the past year) | -55.1% |
| Above the 52-week low | it is 50.7% above its 52-week low (its lowest price of the past year) | +50.7% |
| Below the 52-week high | it is 55.1% below its highest point of the past year | 55.1% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $151.02 (set on 2026-05-04) | $151.02 |
| Given back of the 52-week move | over the past year its closes ranged ($46.07 to $144.98), and it has given back well over two thirds of its rise from last year’s low — 78% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $80.69 to $83.85. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 78.0% |
| From the all-time high | it is 55.1% below its all-time high | -55.1% |
| Nearest price level | it is trading 22.4% below a resistance level at $83.09 — a price it turned at four times since 2025-10-20, most recently on 2026-08-14. Since 2024-10-08 it has 7 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +22.4% |
| All-time low | its lowest closing price on record is $4.03 (set on 2020-04-16) | $4.03 |
| Above the all-time low | it is 1584.1% above its all-time low | +1,584% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.02 between its high and its low — about 7.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.02 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $67.38 and $89.32 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $67.38 – $78.35 – $89.32 |
| Typical daily range (% of price) | its price moves about 7.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.4% |
| Stretch from the 200-day average | it is trading 7.2 daily ranges below its 200-day average price (34.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest | 2.15× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 2.4% since the prior reading | -2.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.02 toward sell |
Candlestick patterns
3
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 2.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.9% |
|---|---|---|
| Gap filled | a 5.1% gap up opened on 2026-09-30 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 5 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 28.1 percentage points (the stock lost 27.0% while the market gained 1.0%) | -28.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 41.5 percentage points (the stock lost 37.7% while the market gained 3.8%) | -41.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 58.0 percentage points (the stock lost 40.6% while the market gained 17.5%) | -58.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 22.1 percentage points (the stock gained 37.1% while the market gained 15.0%) | +22.1% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 12.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -24.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 33% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $101.51 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -33.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 17% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $82.19 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -17.4% |
Price levels it has turned at before
CELC last closed at $67.87 on 2026-10-08. Since 2024-10-08 it has turned at 7 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $83.09 | Resistance | 22.4% above the last close | turned there four times · 2025-10-20 to 2026-08-14 |
| $44.73 | Support | 34.1% below the last close | turned there twice · 2025-10-02 to 2025-10-14 |
| $97.81 | Resistance | 44.1% above the last close | turned there four times · 2025-12-18 to 2026-09-03 |
| $103.36 | Resistance | 52.3% above the last close | turned there twice · 2025-11-25 to 2026-03-03 |
| $14.54 | Support | 78.6% below the last close | turned there twice · 2024-11-01 to 2025-07-14 |
| $13.32 | Support | 80.4% below the last close | turned there four times · 2024-12-09 to 2025-06-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $98.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 20 trading days, since 2026-09-11.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Unusually heavy trading volume · Broke down to a new 20-day low · Analyst price target recently CUT · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$156.91 range $130.00 – $177.00; median $157.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CELC
- Consensus EPS estimate-$1.51 next reporting period, as of 2026-10-07
- Estimate change, 30 days$0.00 from -$1.51, on 2026-09-02, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on the success of a single lead product candidate, gedatolisib.","Risks associated with clinical trial outcomes and regulatory approval processes.","Significant financial risks related to ongoing R&D expenditures and dependence on capital for operations."]
What changed in the latest 10-Q
AI-assisted comparison of CELC's 10-Q filed 2026-08-13 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states the company is a biotechnology company focused on developing and commercializing targeted therapies; older filing described Celcuity as a clinical-stage biotechnology company focused on development.
- Newer filing identifies REVTORPYK (gedatolisib) as the company's first FDA-approved product.
- Newer filing states VIKTORIA-1 data is the basis for FDA approval of REVTORPYK for HR+/HER2- ABC without a PIK3CA mutation following progression on or after at least one line of endocrine therapy in the metastatic setting.
- Newer filing states results for the PIK3CA mutant cohort of the VIKTORIA-1 study have been released.
- Newer filing added a new section titled 'FDA Approval of REVTORPYK' describing the January 2026 NDA acceptance, Priority Review, PDUFA goal date of July 17, 2026, and FDA approval on July 14, 2026.
- Newer filing states REVTORPYK was recommended by NCCN as a preferred Category 1 second-line and/or subsequent-line therapy for HR+/HER2- breast cancer without a PIK3CA mutation following progression on or after at least one line of endocrine therapy.
- Newer filing states the commercialization infrastructure build-out for REVTORPYK launch is complete and commercial launch activities commenced immediately after approval.
- Newer filing states shipments of REVTORPYK are expected to begin late in the third quarter of 2026.
- Newer filing states an Expanded Access Program (EAP) was opened in August 2026 to provide gedatolisib to eligible patients prior to commercial availability and distribution to physicians has begun.
- Newer filing changed description of Phase 1b/PI3K inhibitor comparison wording, stating 26% of patients discontinued alpelisib 'due to AEs' rather than 'due to treatment related AEs' as in older filing.
- Newer filing changed the language about gedatolisib clinical development status by removing the description of the Phase 1b trial and patient enrollment statistics that appeared in the older filing.
- Removed:
- Older filing stated as of March 31, 2026, 1,127 patients and healthy volunteers had received gedatolisib in 12 completed or ongoing clinical trials, including 123 patients treated as single agent, 36 healthy volunteers, and 968 patients in combination with other agents.
- Older filing stated additional patients received gedatolisib in combination with other anti-cancer agents in 10 investigator-sponsored clinical trials.
- Older filing included an entire subsection titled 'B2151009 Phase 1b Trial' describing a Phase 1b dose-finding trial, including dosing details, 138 patients dosed, four patients continuing treatment for more than six years, and expansion arm data.
- Older filing described VIKTORIA-1 as having reported detailed results for Study 1 (PIK3CA WT) and announced topline results for Study 2 (PIK3CA MT).
- Reworded:
- Newer filing changed the opening description of the company from 'clinical-stage biotechnology company focused on the development of targeted therapies' to 'biotechnology company focused on developing and commercializing targeted therapies'.
- Newer filing changed the description of gedatolisib's regulatory status by adding FDA approval information for REVTORPYK.
- Newer filing changed 'In addition, 26% of patients discontinued alpelisib due to treatment related AEs' to 'In addition, 26% of patients discontinued alpelisib due to AEs'.
- Newer filing changed the description of VIKTORIA-1 results from 'reported detailed results for Study 1... and announced topline results for Study 2' to a statement that data from this trial is the basis for FDA approval and results for the PIK3CA mutant cohort have been released.
- Newer filing restructured the MD&A by adding an 'FDA Approval of REVTORPYK' section and removing the 'B2151009 Phase 1b Trial' subsection.
- Notes:
- The newer filing text is truncated and ends mid-sentence at 'Based on our analysis of published epidemiological data, we estimate that approximately 37,000 patients'.
- The older filing text is also truncated and ends mid-sentence at '103 patients were enrolled in one of four expansion arms (A, B, C, D) to determine if the triplet combin'.
- Comparison is limited to the portions of each filing that were provided.
Risk Factors
- Added:
- Newer filing adds Item 2 disclosure: "Recent Unregistered Sales of Equity Securities: None."
- Newer filing adds exhibit 4.1 (Second Supplemental Indenture, dated as of June 8, 2026, between Celcuity Inc. and U.S. Bank Trust Company, National Association, as trustee).
- Newer filing adds exhibit 4.2 (Form of certificate representing the 0.250% Convertible Senior Notes due 2032).
- Newer filing adds exhibit 10.1 (Celcuity Inc. 2026 Stock Incentive Plan).
- Newer filing adds exhibit 10.2 (Celcuity Inc. Amended and Restated 2017 Employee Stock Purchase Plan).
- Newer filing adds exhibit 10.3 (Form of Stock Option Agreement pursuant to the Celcuity Inc. 2026 Stock Incentive Plan).
- Newer filing adds exhibit 10.4 (Form of Stock Option Agreement (Performance-Based)).
- Newer filing adds exhibit 10.5 (Form of Stock Option Agreement (Stock Price Hurdles)).
- Newer filing adds exhibit 10.6 (Form of Restricted Stock Agreement).
- Newer filing adds exhibit 10.7 (Form of Restricted Stock Unit Agreement).
- Newer filing adds exhibit 10.8 (Form of Restricted Stock Unit Agreement (Non-Employee Directors)).
- Newer filing adds exhibit 10.9 (Form of Performance Stock Unit Agreement).
- Newer filing adds exhibit 10.10 (Form of Performance Stock Unit Agreement (Stock Price Hurdles)).
- Newer filing adds exhibit 10.11 (Form of Stock Appreciation Rights Agreement).
- Newer filing adds exhibit 101.INS and 101.SCH (Inline XBRL instance document and taxonomy extension schema).
- Removed:
- Older filing's Item 2 includes a detailed disclosure of warrant exercises during the three months ended March 31, 2026 (45,788 shares issued, with specifics on 43,611 and 2,177 shares); this disclosure is absent from the newer filing.
- Older filing lists exhibit 101 without separate 101.INS and 101.SCH entries; newer filing splits these into two exhibits.
- Reworded:
- Older filing title heading appears as "ITEM 1A. Risk Factors"; newer filing appears as "ITEM 1A. Risk Factors" with no substantive difference in the Risk Factors section text.
- Older filing's Item 5 Trading Plans disclosure covers the three months ended March 31, 2026; newer filing's covers the three months ended June 30, 2026.
- Older filing's exhibit 101 description refers to the quarter ended March 31, 2026; newer filing's 101.INS refers to the quarter ended June 30, 2026.
- Older filing's signature date is May 14, 2026; newer filing's signature date is August 13, 2026.
- Notes:
- The Risk Factors section itself is identical in substance: both filings state there have been no material changes to risk factors disclosed in the 2025 10-K.
- The comparison includes Part II items and exhibits because they appear within the provided source text labeled as the Risk Factors section in both filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 2 sells ($318M) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 9 sells ($323M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-14. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CELC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CELC as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 6,017,272
- Reported value $629,519,872
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CELC's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CELC had 11,360,367 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CELC had 23.2% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.48 days to cover at the same settlement.
- Reported short interest (shares) 11,360,367
- Short interest (% of shares outstanding) 23.2%
- Prior settlement (shares) 10,688,163
- Reported change 6.29%
- Days to cover (reported) 12.48
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CELC vs…
CELCUITY INC is found in…
Frequently asked questions
What does CELCUITY INC (CELC) do?
Celcuity is a clinical-stage biotechnology company focused on the development and commercialization of targeted therapies for cancer patients. Its lead product candidate is gedatolisib (brand name REVTORPYK), a potent inhibitor of PI3K/mTOR, which the company is evaluating in various clinical trials for cancer treatment. The company holds exclusive global rights for the development and commercialization of gedatolisib through a license agreement with Pfizer.
What sector is CELCUITY INC (CELC) in?
CELCUITY INC (CELC) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CELCUITY INC's (CELC) competitors?
Notable peers of CELCUITY INC (CELC) include Novartis, AstraZeneca, Eli Lilly, Pfizer and Roche. This peer set is informational only — not financial advice.
Is CELCUITY INC (CELC) overbought or oversold right now?
CELCUITY INC (CELC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 31, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CELC come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.